Elanco’s Post

Elanco ended 2023 with momentum, returning to constant currency revenue growth for the full year and delivered the second consecutive quarter of constant currency revenue growth of 5% in the fourth quarter. In 2023, we returned the company to growth, doubled innovation sales and exceeded debt pay down, by paying down $76 million dollars of gross debt.  Looking forward, we expect our existing portfolio to deliver constant currency revenue growth of 1% to 3% in 2024, before the potential upside of our three late-stage pipeline products with a path toward approval in the first half of 2024. We see growth in both Pet Health and Farm Animal as well as in the U.S. and International. Our team has taken disciplined, decisive actions to improve our earnings potential and leverage profile over time, as evidenced by: • The sale of our aqua business for over a billion dollars of net proceeds; • The restructuring announced today to reallocate resources to higher value creation areas with greater earnings potential; notably Pet Heath and Livestock Sustainability • Our investment in expanding our U.S. pet health field force to enhance share of voice and maximize innovation in our highest margin business area; and • Our focused efforts to manage manufacturing throughput to improve net working capital performance, while investing to support the launch of differentiated products in the years to come. We believe the strategic decisions we are taking will provide the foundation to enable sustained revenue growth and value creation over the medium and long term. We want to thank the global Elanco team for a successful 2023 as well as our amazing customers - farmers, veterinarians and pet owners around the world. We do believe our mission of "Making Animals Lives Better, Makes Life Better” has never been more significant than it is today. Read the full press release, https://bit.ly/48A4R18. #WeAreElanco 

◼ Elanco Announces Sale of Aqua Business for $1.3 Billion 👉Transaction reinforces Elanco’s commitment to most significant value creation opportunities in pet health and livestock sustainability Enables company to accelerate debt paydown by $1.05B to $1.1B 👉This strategic decision was the outcome of a disciplined process over the last year and allows us to concentrate our investment in areas we believe have greater earnings potential over the medium and long term – Pet Health & Livestock Sustainability. As we’ve said before, we are focused on delivering consistent high-impact innovation and continue to have confidence in our late-stage pipeline with six potential blockbuster products expected in the U.S. market by 2025. Further, with the proceeds from this transaction in combination with improved free cash flow from the business, we expect net debt to adjusted EBITDA in the high-3x to low-4x range by the end of 2025. Thank you to the aqua team for your contributions, hard work and dedication to deliver value to our customers who rely on our products and solutions. This year presents significant potential for Elanco that will require focused execution globally as we navigate 2024. Click here to read the full press release: 👇 https://bit.ly/3SLgSfy #كيوفيتيك #qualified_veterinary_technology #QNews #Qvetech

+14.2% revenue growth; +15.9% EBITA (underlying) growth. Opex +0.6% LFL vs PCP This week Apiam Animal Health Limited (AHX:ASX) provided a trading update for the first four months of FY24. Some key points included: * FY24 YTD trading (Jul - Oct 2023): +14.2% revenue growth; +15.9% EBITA (underlying) growth vs PCP * Dairy & mixed animal segment continues to drive resilient business growth and accounts for 79% of Group revenues. * Beef feedlot performance significantly improved from prior years - +9% vs PCP * Acquisitions executed in FY23 performing strongly (+7% revenue) under Apiam's ownership * Cost-savings programs implemented across the business delivering improved earnings margins From an earnings perspective, we are making progress but still have work to do. Apiam has strong fundamentals as we continue to strive towards delivering improved financial results. You can read the full AGM Address at the link at https://lnkd.in/ges7zNPg

"Strong FY24 results: 11% underlying growth" For the year ended 31st March 2024, ECO Animal Health Group reported revenue +5%YoY at £89.4m, which on a currency-adjusted basis was +11%YoY, and (adj.) EBITDA of £8.0m, +11.2%YoY which was ahead of market consensus on an improvement in margin from 8.5% to 9.0%. The impact of currency volatility was evident in gross profitability at 42.1% compared to 45.0% a year earlier; H2 recovered to 43.1%. (Adj.) EBIT was 14%YoY lower at £4.6m, a 5.1% margin compared to 6.3% in FY23. Having rallied 30%YoY, EAH shares are trading 7% off its recent year high. We have derived a Fair Value per share range of 137p-146p based on the initial, medium-term, valuation of the pipeline of products under development. Link to note: https://lnkd.in/e5NcFrs8

Ajooni Biotech, a vegetarian animal healthcare solutions provider, has secured a Rs 4.95 crore order from a top Indian dairy supplier. The company provides a wide range of cattle feed products. Note: Investment in securities market is subject to market risks. Read all the related documents carefully before investing. Dalal Street Investment Journal, DSIJ, Capital Market, Stock Market, DSIJ, Financial Advisors @dalalstreetinvjournal #dsij #stockmarketindia #stockmarketinvesting #stockmarketanalysis #financialupdates #economictrends #indianstocks #marketwatch #businessnews #investmentopportunities #economicgrowth #stockmarketanalysis #indianstocks #nse #bse #nifty #nifty50 #nifty50 #sensex #sensextoday #stockmarketupdate #marketvolatility #investmenttips

Merck Expands Aquatic Portfolio with $1.3 Billion Acquisition of Elanco's Aqua Business Pharmaceutical giant Merck has announced its acquisition of Elanco Animal Health's aqua business for $1.3 billion in cash. The deal, set to be finalised by mid-year, positions Merck as a dominant force in the aquatic pet health products market. Elanco's shares experienced an uptick of 7%, reaching $15.8 in premarket trading following the announcement. This move aligns with Merck's previous endeavours in animal health, having acquired fish health product maker Scan Aqua and fish conservation monitoring equipment manufacturers Vaki and Antelliq Corp in 2019. The acquisition provides Merck with access to products like Clynav, a DNA-based vaccine safeguarding Atlantic salmon against pancreas disease, and Imvixa, an anti-parasitic treatment for sea lice. Beyond innovative products, Merck stands to gain from Elanco's manufacturing facilities in Canada and Vietnam, along with a research facility in Chile, further strengthening Merck's position in the rapidly growing aquaculture sector. For Elanco, the transaction will significantly reduce its debt by $1.05 billion to $1.1 billion, constituting a 20% reduction. The company aims to redirect these funds towards investments in its pet healthcare products, which are deemed to yield higher returns per dollar spent. Elanco's CEO, Jeff Simmons, emphasises the company's focus on pet health and livestock sustainability, with six late-stage products in the pipeline set to launch in the US market by 2025, pending approval. The aqua business, contributing $42 million in total sales during the third quarter, accounts for approximately 4% of Elanco's overall revenue. Will be interesting to see how this acquisition from Merck develops going forward. See on Crowwd here: https://lnkd.in/esbkT2cz Sources: https://lnkd.in/e_uRH5aM #healthcare #equities #markets #news

Is methionine the 3rd limiting amino acid

Elanco’s second quarter results – exceeding expectations and delivering sequential improvement in underlying performance – reflect our global team’s deep commitment to our customers and the impact that reaching the world’s animals can have.     Our Elanco team has been laser-focused on delivering value for customers and shareholders, and it showed in our results, exceeding the top end of the range for all targets and raising guidance for the year. We delivered a strong second quarter with continued sequential improvement in our underlying business, meaningful progress in our late-stage pipeline, and the successful completion of our ERP integration.    Industry-leading, differentiated innovation will drive our long-term sustained growth and value. We are delivering new solutions to some of our customers’ greatest challenges from diabetes in cats and a treatment for deadly parvovirus in puppies to environmental solutions for livestock. And are making exciting progress on our next wave of differentiated innovation. Thank you to our customers – veterinarians, farmers, producers – what you do has never mattered more.      Importantly, Elanco has reached an inflection point with our standup and integration now behind us. We’ve built an optimized infrastructure to deliver our next era of innovation, growth and value creation for customers and shareholders. It’s clear. Making life better for animals, makes life better.     #WeAreElanco     Read the full press release, https://bit.ly/3QudyER.

Sustainable growth is focused on the intense ability to plan and follow a strategic and effective agenda. We continue on the proposed path to deliver another strong year of expressive results

California Dairies, Inc. (CDI) is pleased to share the recent announcement by Elanco Animal Health that the Food and Drug Administration (FDA) has completed its comprehensive, multi-year review of Bovaer® (3-NOP), a first-in-class methane-reducing feed ingredient, and determined the product meets safety and efficacy requirements for use in lactating dairy cattle. “CDI is excited about a solution for the reduction of enteric methane, which has followed the rigorous review of the FDA and created a path forward for future interventions that the entire supply chain can feel comfortable with,” said Darrin Monteiro, CDI’s Vice President of Sustainability and Member Relations. This is a critical milestone for dairy farmers, food companies, consumers, and the environment, creating value for farmers while helping meet sustainability goals. Feeding one tablespoon of Bovaer per lactating dairy cow per day can reduce methane emissions by about 30% or approximately 1.2 metric tons of carbon dioxide equivalent (CO2e) emissions annually. To learn more, please visit Elanco’s official press release: https://lnkd.in/gkEYf_9F #CDI #Sustainability #Enteric #Methane #Emissions